Full 3rd. Circ. Won't Retread Avandia Marketing Decision
The full Third Circuit declined Tuesday to reconsider a panel's ruling that GlaxoSmithKline must face a lawsuit brought by union health and welfare funds over marketing of its diabetes drug Avandia...To view the full article, register now.
Already a subscriber? Click here to view full article